Search Results - "Mocci G"

An inverse propensity score-weighted comparison between Vedolizumab, Ustekinumab, and Tofacitinib in ulcerative colitis patients refractory or intolerant to anti-TNF therapies.

Authors: Mocci, G. Savarino, E. V. Bertin, L. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi2367-i2368. 2p.

Real-world effectiveness and safety of three JAK inhibitors for ulcerative colitis: an IPTW analysis from IN-IBD.

Authors: Mocci, G. Pasta, A. Elisei, W. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi302-i303. 2p.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Effect of IL-23 inhibitors on extra-intestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease.

Authors: Truyens, M. Tolstoy, X. Calabrese, G. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi2069-i2073. 5p.

Effect of JAK inhibitors on extra-intestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease.

Authors: Truyens, M. Tolstoy, X. Calabrese, G. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi2000-i2004. 5p.

MIRACLE-UC: Mirikizumab Investigation of Real-world Assessment of Clinical and Long-term Effectiveness and Adverse Events in Patients with Ulcerative Colitis - A Multicenter Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Authors: Barberio, B. Todeschini, A. Laterza, L. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi1625-i1628. 4p.

Upadacitinib: Personalized Goals for Remission and Disease Evaluation in Patients with Crohn’s Disease (UPGRADE-CD) - A Multicenter Prospective Study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

Authors: Barberio, B. Scaldaferri, F. Bezzio, C. et al.

Source: Journal of Crohn's & Colitis. 2026 Supplement, Vol. 20, pi174-i176. 3p.

Modeling the starch retrogradation kinetic of durum wheat bread

Authors: Del Nobile, M.A. Martoriello, T. Mocci, G. et al.

Source: Journal of Food Engineering. Sep2003, Vol. 59 Issue 2/3, p123. 6p.

Subjects: Wheat, Bread, Starch

Performance of GPT-5 in the Interpretation of IBD Colonoscopy and Histopathology Reports.

Authors: Maida, M Vitello, A Macaluso, F S et al.

Source: Endoscopy. 2026, Vol. 58 Issue 12, pS377-S378. 2p.

Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants

Authors: Andrisani, G. Frasca, D. Romero, M. et al.

Source: Journal of Crohn's & Colitis. May2013, Vol. 7 Issue 4, p301-307. 7p.

P306 Efficacy and safety of low-molecular weight heparin for the prevention of venous thromboembolism in patients with severe ulcerative colitis

Authors: Papa, A. Armuzzi, A. Guidi, L. et al.

Source: Journal of Crohn's & Colitis. Feb2012 Supplement 1, Vol. 6, pS132-S132. 1p.

P305 Predictive factors of one-year mucosal healing in a cohort of ulcerative colitis patients in treatment with infliximab

Authors: Andrisani, G. Armuzzi, A. Felice, C. et al.

Source: Journal of Crohn's & Colitis. Feb2012 Supplement 1, Vol. 6, pS131-S131. 1p.

P248 Infliximab in steroid-dependent ulcerative colitis: Efficacy and predictors of clinical and endoscopic remission

Authors: Armuzzi, A. Pugliese, D. Danese, S. et al.

Source: Journal of Crohn's & Colitis. Feb2012 Supplement 1, Vol. 6, pS108-S108. 1p.

P031 - Mucosal healing and risk of colectomy in ulcerative colitis patients

Authors: Papa, A. De Vitis, I. Armuzzi, A. et al.

Source: Journal of Crohn's & Colitis. Feb2009, Vol. 3 Issue 1, pS23-S23. 1p.

An inverse probability of treatment weighted comparison between vedolizumab, ustekinumab, and tofacitinib in anti-TNF-experienced ulcerative colitis patients.

Authors: Tursi A Pasta A Elisei W et al.

Corporate Authors: Tursi A Pasta A Elisei W et al.

Source: Therapeutic advances in gastroenterology [Ther Adv Gastroenterol] 2026 Jun 15; Vol. 19, pp. 17562848261455563. Date of Electronic Publication: 2026 Jun 15 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Sage Publications Country of Publication: England NLM ID: 101478893 Publication Model: eCollection Cited Medium: Print ISSN: 1756-283X (Print) Linking ISSN: 1756283X NLM ISO Abbreviation: Ther Adv Gastroenterol Subsets: PubMed not MEDLINE

Nerve growth factor responsive elements modulate immune cell inflammation and are dysregulated in an Alzheimer's disease mouse model.

Authors: Gera R Mocci G Tambaro S et al.

Source: Frontiers in immunology [Front Immunol] 2026 Apr 23; Vol. 17, pp. 1722477. Date of Electronic Publication: 2026 Apr 23 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Performance of GPT-5 in the Interpretation of IBD Histopathology Reports.

Authors: Maida M Vitello A Macaluso FS et al.

Source: United European gastroenterology journal [United European Gastroenterol J] 2026 Feb; Vol. 14 (1), pp. e70161. Date of Electronic Publication: 2025 Dec 17.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 101606807 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2050-6414 (Electronic) Linking ISSN: 20506406 NLM ISO Abbreviation: United European Gastroenterol J Subsets: MEDLINE